Reni Benjamin
Stock Analyst at Citizens
(1.38)
# 3,526
Out of 5,072 analysts
163
Total ratings
37.59%
Success rate
-14.02%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $7.48 | +60.43% | 15 | Oct 31, 2025 | |
| ALLO Allogene Therapeutics | Reiterates: Market Perform | n/a | $1.46 | - | 8 | Aug 4, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $84.12 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.64 | +210.66% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.90 | +10.62% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $104.46 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.65 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.00 | +300.00% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.57 | +155.59% | 1 | Aug 8, 2022 | |
| ADVM Adverum Biotechnologies | Upgrades: Market Perform | n/a | $4.12 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.16 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.86 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $19.18 | -47.86% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $4.30 | +16.28% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $12.14 | +130.64% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $12.76 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $17.89 | +123.59% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.47 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.65 | +142.42% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.92 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.25 | -13.51% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $48.96 | +22.55% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.79 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $215.62 | +46.09% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $87.54 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $266.28 | -0.48% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $4.09 | +315.65% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $13.39 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.54 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $33.26 | -63.92% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $28.76 | - | 1 | Nov 15, 2017 |
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $7.48
Upside: +60.43%
Allogene Therapeutics
Aug 4, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.46
Upside: -
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $84.12
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.64
Upside: +210.66%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.90
Upside: +10.62%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $104.46
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.65
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.00
Upside: +300.00%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.57
Upside: +155.59%
Adverum Biotechnologies
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $4.12
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.16
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.86
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $19.18
Upside: -47.86%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $4.30
Upside: +16.28%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $12.14
Upside: +130.64%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $12.76
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $17.89
Upside: +123.59%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.47
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.65
Upside: +142.42%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.92
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.25
Upside: -13.51%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $48.96
Upside: +22.55%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.79
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $215.62
Upside: +46.09%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $87.54
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $266.28
Upside: -0.48%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $4.09
Upside: +315.65%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $13.39
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.54
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $33.26
Upside: -63.92%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $28.76
Upside: -